
1. semin liver dis. 2005;25 suppl 1:29-39.

clinical trial results new therapies hbv: implications treatment
guidelines.

gish rg(1).

author information: 
(1)department medicine, division hepatology complex gi, physicians
foundation, california pacific medical center, san francisco, california 94115,
usa. gishr@sutterhealth.org

currently approved treatments chronic infection hepatitis b virus (hbv) 
are limited low rates sustained response, side effects, cases, 
the emergence drug resistance. thus, new treatments, characterized more
potent antiviral effects less toxicity, minimal risk resistance, are
needed. last years, several agents developed have
increased potency reduced potential resistance--among them, entecavir and
pegylated interferons. addition, several novel anti-hbv agents recently
evaluated phase ii clinical trials, tenofovir, clevudine, telbivudine,
pradefovir, valtorcitabine, appear promising agents treatment
of chronic hepatitis b. article describes clinical experience new
antiviral agents implications trial results practice
guidelines.

doi: 10.1055/s-2005-915648 
pmid: 16103979  [indexed medline]

